Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series
SEATTLE, Feb. 07, 2024 -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistanc ...